Acrivon Therapeutics Management
Management criteria checks 2/4
Acrivon Therapeutics' CEO is Peter Blume-Jensen, appointed in Mar 2018, has a tenure of 6.67 years. total yearly compensation is $6.47M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 5.84% of the company’s shares, worth $11.91M. The average tenure of the management team and the board of directors is 2.6 years and 2.9 years respectively.
Key information
Peter Blume-Jensen
Chief executive officer
US$6.5m
Total compensation
| CEO salary percentage | 9.7% |
| CEO tenure | 6.7yrs |
| CEO ownership | 5.8% |
| Management average tenure | 2.6yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Nov 17
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Sep 18Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?
Jul 17Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$77m |
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$64m |
| Dec 31 2023 | US$6m | US$629k | -US$60m |
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$22m | US$536k | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$757k | US$430k | -US$16m |
Compensation vs Market: Peter's total compensation ($USD6.47M) is above average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Blume-Jensen (61 yo)
6.7yrs
Tenure
US$6,465,973
Compensation
Mr. Peter Blume-Jensen, MD, PhD., serves as a Member of Advisory Board at Kernal Biologics, Inc. Mr. Blume-Jensen is the Founder, Chairman, President, Chief Executive Officer and Acting Chief Scientific Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.7yrs | US$6.47m | 5.84% $ 11.9m | |
| Co-Founder | no data | US$739.78k | 0.97% $ 2.0m | |
| Chief Legal Officer | 2.1yrs | US$697.00k | 0.048% $ 97.2k | |
| Chief Financial Officer | 2.6yrs | US$2.30m | 0.053% $ 108.1k | |
| Chief Operating Officer | 2.3yrs | US$2.18m | 0.16% $ 335.2k | |
| Vice President of Finance & Accounting | no data | no data | 0.015% $ 29.7k | |
| Senior VP and Head of Investor Relations & Corporate Affairs | 1.3yrs | no data | no data | |
| Vice President of Quality & Compliance | 2.6yrs | no data | no data | |
| VP & Head of Human Resources | 1.8yrs | no data | no data | |
| Chief Development Officer | 3.7yrs | US$538.08k | 0.022% $ 45.5k | |
| Academic Co-Founder | no data | no data | no data | |
| VP & Head of Data Science | 2.6yrs | no data | no data |
2.6yrs
Average Tenure
51yo
Average Age
Experienced Management: ACRV's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.7yrs | US$6.47m | 5.84% $ 11.9m | |
| Co-Founder | 6.7yrs | US$739.78k | 0.97% $ 2.0m | |
| Academic Co-Founder | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | less than a year | no data | 0.012% $ 23.7k | |
| Independent Director | 4.1yrs | US$58.13k | 0.063% $ 128.2k | |
| Independent Director | 2.1yrs | US$68.13k | 0.063% $ 128.2k | |
| Independent Director | 1.4yrs | US$325.07k | 0.032% $ 65.0k | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | less than a year | no data | 0.0087% $ 17.7k | |
| Independent Director | 3yrs | US$65.00k | 0.063% $ 128.2k | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
57yo
Average Age
Experienced Board: ACRV's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.